0000899243-21-010270.txt : 20210308 0000899243-21-010270.hdr.sgml : 20210308 20210308082043 ACCESSION NUMBER: 0000899243-21-010270 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200831 FILED AS OF DATE: 20210308 DATE AS OF CHANGE: 20210308 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Cardama Alfonso Quintas CENTRAL INDEX KEY: 0001760104 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38811 FILM NUMBER: 21720695 MAIL ADDRESS: STREET 1: C/O TCR2 THERAPEUTICS INC. STREET 2: 100 BINNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02142 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: TCR2 THERAPEUTICS INC. CENTRAL INDEX KEY: 0001750019 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 474152751 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 100 BINNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: 617-949-5200 MAIL ADDRESS: STREET 1: 100 BINNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02142 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2020-08-31 0 0001750019 TCR2 THERAPEUTICS INC. TCRR 0001760104 Cardama Alfonso Quintas TCR2 THERAPEUTICS INC. 100 BINNEY STREET CAMBRIDGE MA 02142 0 1 0 0 Chief Medical Officer Common Stock 2020-08-31 5 A 0 E 1118 10.098 A 3043 D Common Stock 2021-02-28 5 A 0 E 708 16.1245 A 3751 D The reporting person is voluntarily reporting the acquisition of shares of the issuer's common stock pursuant to the issuer's 2018 Employee Stock Purchase Plan ("ESPP") for the ESPP purchase period of March 1, 2020 through August 31, 2020. This transaction is exempt under Rule 16b-3(c). In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's common stock on February 28, 2020. The reporting person is voluntarily reporting the acquisition of shares of the issuer's common stock pursuant to the ESPP for the ESPP purchase period of September 1, 2020 through February 28, 2021. This transaction is exempt under Rule 16b-3(c). In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's common stock on September 1, 2020. /s/ Margaret Siegel as Attorney-in-Fact 2021-03-08